Patents by Inventor Kevin Kreutter

Kevin Kreutter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240262830
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of IRE1?, and the treatment of IRE1?-mediated disorders.
    Type: Application
    Filed: February 2, 2021
    Publication date: August 8, 2024
    Inventors: Kevin KREUTTER, Lewis WHITEHEAD, Donna L. ROMERO, Steven K. ALBANESE, Heidi KOLDSOE, Andreas VERRAS
  • Patent number: 11492341
    Abstract: The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: November 8, 2022
    Assignee: Nimbus Artemis, Inc.
    Inventors: Silvana Marcel Leit de Moradei, Kevin Kreutter, H. James Harwood, Eric Therrien
  • Publication number: 20200157076
    Abstract: The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.
    Type: Application
    Filed: November 15, 2019
    Publication date: May 21, 2020
    Inventors: Silvana Marcel Leit de Moradei, Kevin Kreutter, H. James Harwood, Eric Therrien
  • Patent number: 8748624
    Abstract: The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: June 10, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Devraj Chakravarty, Kevin Kreutter, Mark Powell, Brian Shook, Fengbin Song, Guozhang Xu, Shyh-Ming Yang, Rui Zhang, Bao-Ping Zhao
  • Publication number: 20120302610
    Abstract: The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: May 23, 2012
    Publication date: November 29, 2012
    Inventors: Devraj Chakravarty, Kevin Kreutter, Mark Powell, Brian Shook, Fengbin Song, Guozhang Xu, Shyh-Ming Yang, Rui Zhang, Bao-Ping Zhao
  • Patent number: 7829584
    Abstract: The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: November 9, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark R. Player, Tianbao Lu, Huaping Hu, Xizhen Zhu, Christopher Teleha, Kevin Kreutter
  • Publication number: 20070225282
    Abstract: The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.
    Type: Application
    Filed: March 13, 2007
    Publication date: September 27, 2007
    Inventors: Mark Player, Tianbao Lu, Huaping Hu, Xizhen Zhu, Christopher Teleha, Kevin Kreutter
  • Patent number: 7262210
    Abstract: The present invention describes compounds of Formula I or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: August 28, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Kevin Kreutter, Tianbao Lu, Yu Kai Lee, Christopher Teleha, Mark Player, Xizhen Zhu
  • Publication number: 20070021436
    Abstract: The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula C: wherein R1, R2, R99, and X are as defined herein, the use of such compounds in the sysnthesis of protein tyrosine kinase inhibitors, particularly inhibitors of FLT3 and/or c-kit and/or TrkB.
    Type: Application
    Filed: June 6, 2006
    Publication date: January 25, 2007
    Inventors: Nand Baindur, Michael Gaul, Kevin Kreutter, Guozhang Xu
  • Publication number: 20070004763
    Abstract: The invention is directed to aminoquinoline and aminoquinazoline compounds of Formula I: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: June 6, 2006
    Publication date: January 4, 2007
    Inventors: Nand Baindur, Michael Gaul, Kevin Kreutter, Christian Baumann, Alexander Kim, Guozhang Xu, Bao-Ping Zhao
  • Publication number: 20060281772
    Abstract: The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: June 6, 2006
    Publication date: December 14, 2006
    Inventors: Nand Baindur, Michael Gaul, Kevin Kreutter, Christian Baumann, Alexander Kim, Guozhang Xu, Robert Tuman, Dana Johnson
  • Publication number: 20060281768
    Abstract: The invention is directed to thienopyrimidines and thienopyridines compounds of Formula I and Formula II: where R1, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: June 6, 2006
    Publication date: December 14, 2006
    Inventors: Michael Gaul, Kevin Kreutter, Christian Baumann
  • Publication number: 20060241148
    Abstract: The present invention describes compounds of Formula I or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.
    Type: Application
    Filed: March 21, 2006
    Publication date: October 26, 2006
    Inventors: Kevin Kreutter, Tianbao Lu, Yu Lee, Christopher Teleha, Mark Player, Xizhen Zhu